Q32 Bio Inc (QTTB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.54 (-2.95%), Market cap $0.09B, P/E ratio 1.93, 52-week low–high $1.36 ~ $7.30.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well
Financial statements, price targets, institutional (13F) holdings and related news for Q32 Bio Inc are updated in real time on BlackAll Trade.
Q32 Bio Inc trades at $10.54 (-2.95%). Real-time quotes and charts are available on BlackAll Trade.
Q32 Bio Inc has a market cap of about $0.09B. Its P/E ratio is 1.93.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven